Bonaca MP, Bauersachs RM, Anand SS, et al. - Given a high risk of major adverse limb and cardiovascular events in patients with peripheral artery disease who have undergone lower-extremity revascularization, researchers focused on the efficacy as well as the safety of rivaroxaban in this context in this double-blind trial. Participants were patients having peripheral artery disease who had undergone revascularization. These participants were randomly allocated to receive rivaroxaban (2.5 mg twice daily) plus aspirin or placebo plus aspirin. A significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes was observed in relation to rivaroxaban at a dose of 2.5 mg twice daily plus aspirin, vs aspirin alone, in patients with peripheral artery disease who had undergone lower-extremity revascularization. The groups showed no significant difference in the incidence of Thrombolysis in Myocardial Infarction major bleeding. A significantly higher incidence of International Society on Thrombosis and Haemostasis major bleeding was reported in relation to treatment with rivaroxaban and aspirin vs with aspirin alone.